

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



March 31, 2026

Company name: Fuso Pharmaceutical Industries, Ltd.
Representative: Mikio Toda, President and Representative Director
(Securities code: 4538, Tokyo Stock Exchange Prime Market)
Inquiries: Corporate Communication Office, Corporate Planning Division
(Telephone (main): +81-6-6969-1131)

Notice Concerning the Conclusion of a Syndicated Loan Agreement

Fuso Pharmaceutical Industries, Ltd. (the “Company”) resolved to conclude a syndicated loan agreement under which Sumitomo Mitsui Banking Corporation serves as the arranger (the “Agreement”), at a resolution of the Board of Directors dated on March 31, 2026. The Company hereby announces the details as follows.

1. Purpose of the Agreement

In its medium-term management plan, FUSO VISION 2030 Next Stage, the Company disclosed a plan to construct a second formulation building (tentative name) within the premises of the Okayama Factory in order to create a new manufacturing line of powder dialysate and to transfer the functions of the Daito Factory to Okayama Factory for consolidation (the “Plan”). For the Company, which holds around 50% of the domestic market share for dialysis supplies in terms of the number of patients, the Plan not only further strengthens the stable supply system but is regarded as the most important strategy toward achieving a “market share of 55%,” which is the target for fiscal year 2030.

The Company decided to raise funds for the Plan through a syndicated loan with Sumitomo Mitsui Banking Corporation serving as the arranger, after careful consideration of capital efficiency and financial soundness. This agreement is based on a commitment-type term loan and includes an associated guaranteed scheme, etc.

The Company will continue to pursue sustainable growth and enhance corporate value through close cooperation with each of the financial institutions.

2. Details of the syndicated loan

| | |
|--------------------------------------|--|
| Type of agreement | Commitment-type term loan |
| Total facility amount | 13.4 billion yen |
| Execution date | March 31, 2026 |
| Commitment period | September 30, 2026 to February 15, 2029 |
| Arranger | Sumitomo Mitsui Banking Corporation |
| Participating financial institutions | Sumitomo Mitsui Banking Corporation; Sumitomo Mitsui Trust Bank, Limited; Resona Bank, Limited; The Hokuriku Bank, Ltd.; MUFG Bank, Ltd.; The Chugoku Bank, Ltd.; The Joyo Bank, Ltd.; and Mizuho Bank, Ltd. |

3. Impact on financial results

The impact of the conclusion of the Agreement on the financial results for the fiscal year ending March 31, 2026 is immaterial.